ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.5500-0.0600 (-3.73%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	1.6100
Open	1.5900
Bid	1.5500 x 21500
Ask	1.5600 x 21500
Day's Range	1.5500 - 1.6025
52 Week Range	1.3800 - 3.7100
Volume	640,018
Avg. Volume	2,504,410

Market Cap	198.694M
Beta (5Y Monthly)	1.30
PE Ratio (TTM)	N/A
EPS (TTM)	-0.7750
Earnings Date	Aug 03, 2021 - Aug 09, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	8.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Zacks
Will Adma Biologics (ADMA) Report Negative Q2 Earnings? What You Should Know
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.
How Much Did ADMA Biologics'(NASDAQ:ADMA) Shareholders Earn From Share Price Movements Over The Last Five Years?
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we...
GlobeNewswire
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection
Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, N.J. and BOCA RATON, Fla., July 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration (“FDA”) recently completed a Pre-Approval Inspection (